Yunnan Baiyao

同壁财经 · Jun 8 at 06:10 AM

China and the U.S. dual clinical approval, Yunnan Baiyao's first biological innovative drug welcomes a new milestone

Wallstreetcn · Jan 27 at 04:41 AM

With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibited

Wallstreetcn · Nov 4, 2025 at 04:44 PM

"Artificial Intelligence + Healthcare" welcomes new policies, multiple listed companies are expected to benefit

Zhitong · Oct 30, 2025 at 10:44 AM

Yunnan Baiyao released its performance for the first three quarters, with a net profit attributable to the parent company of 4.777 billion yuan, an increase of 10.41%

Zhitong · Oct 30, 2025 at 05:05 AM

Yunnan Baiyao: Net profit in the third quarter was 1.144 billion yuan, a year-on-year increase of 0.55%

Wallstreetcn · Oct 24, 2025 at 08:30 AM

The market value of the hundred billion is in jeopardy! After a 20% plunge in profits, how will "Chinese medicine Moutai" ZZPZH turn the tide?